RxDoctor Payments Data

Felix Eke

Physician Assistant · Bronx, NYNPI 1134481401

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 41.9% of the total. Reporting peaked in 2021 at $2,088 and has fallen 82.0% since, to $376 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,162in general payments, 2019–2025

Across 146 payments — averaging $35.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$958
  • Viiv Healthcare Company$481
  • Genentech USA, Inc.$404
  • Amgen$383
  • Novartis$150
  • plus $623 from 7 others

What the payments were for

  • Food & beverage$5,162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,162 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide118$238,207
OzempicSemaglutide95$114,391
JardianceEmpagliflozin77$90,597
JanuviaSitagliptin Phosphate73$85,876
LinzessLinaclotide32$45,443
MounjaroTirzepatide30$39,431
VascepaIcosapent Ethyl45$32,880
TradjentaLinagliptin31$32,651
Breo ElliptaFluticasone/Vilanterol40$30,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$30,310
Incruse ElliptaUmeclidinium Bromide37$28,767
RybelsusSemaglutide11$25,768
SymbicortBudesonide/Formoterol Fumarate60$22,548
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$16,563
FarxigaDapagliflozin Propanediol13$14,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,163$140,159106 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$108$89,938102 claims
MerckJanuvia$142$85,87673 claims
AbbVieLinzess, Restasis$60$52,11643 claims
AstraZenecaSymbicort, Farxiga$958$36,96673 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →